Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study

Study of 38,731 new users of GLP-1 receptor agonists (GRAs) (liraglutide /exenatide/ lixisenatide/ dulaglutide) matched to new user of DPP-4 inhibitors, found GRAs linked to reduced risk of serious renal events (4.8 vs. 6.3 events /1000 person-years; HR 0.76; 95% CI 0.68–0.85).

Diabetes Care